SOURCE: NuPathe Inc.

NuPathe Inc.

November 09, 2010 16:30 ET

NuPathe to Present at the Lazard Capital Markets 7th Annual Healthcare Conference

CONSHOHOCKEN, PA--(Marketwire - November 9, 2010) - NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces that Jane Hollingsworth, chief executive officer, will present a company overview at the Lazard Capital Markets 7th Annual Healthcare Conference on Tuesday, November 16, 2010 at 8:55 a.m. EST. The conference is being held at the St. Regis Hotel in New York.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company's website for one month following the call. 

About NuPathe
NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, Zelrix™, is a single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.

Contact Information

  • Contact Information:
    John Woolford
    (443) 213-0506
    Email Contact

    Keith A. Goldan
    Vice President, Chief Financial Officer
    NuPathe Inc.
    (484) 567-0130